IL-12-and IL-23 in health and disease

Cytokine and Growth Factor Reviews

Volumn 25, Issue 4, 2014, Pages 415-421

  Croxford, Andrew L ^a   Kulig, Paulina ^a   Becher, Burkhard ^a  

^a UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

Autoimmunity; Cytokines; IL 12 family; Inflammation; Treatment

Indexed keywords

ANTINEOPLASTIC AGENT; APILIMOD; BRIAKINUMAB; BRODALUMAB; CD40 MONOCLONAL ANTIBODY; EGEN 001; GAMMA INTERFERON; GUSELKUMAB; INTERLEUKIN 12; INTERLEUKIN 12P40; INTERLEUKIN 17; INTERLEUKIN 17 RECEPTOR; INTERLEUKIN 1BETA; INTERLEUKIN 22; INTERLEUKIN 23; INTERLEUKIN 23 MONOCLONAL ANTIBODY; INTERLEUKIN 23 RECEPTOR; INTERLEUKIN 23P19; INTERLEUKIN 27; INTERLEUKIN 35; IXEKIZUMAB; METHOTREXATE; MONOCLONAL ANTIBODY; PLACEBO; PROTEIN P40; SECUKINUMAB; STAT3 PROTEIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; USTEKINUMAB;

ANTIINFLAMMATORY ACTIVITY; CANCER GROWTH; COLORECTAL CARCINOMA; CROHN DISEASE; CYTOKINE PRODUCTION; DENDRITIC CELL; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; HUMAN; IMMUNOPATHOGENESIS; IMMUNOREGULATION; INNATE IMMUNITY; LUNG METASTASIS; MALIGNANT NEOPLASTIC DISEASE; MULTIPLE SCLEROSIS; NONHUMAN; OVARY CANCER; PSORIASIS VULGARIS; RHEUMATOID ARTHRITIS; SHORT SURVEY; TH1 CELL; ULCERATIVE COLITIS; ANIMAL; IMMUNOLOGY; INFLAMMATION; INFLAMMATORY BOWEL DISEASE; MOUSE; NEOPLASM; PATHOLOGY; PSORIASIS; TH17 CELL;

ANIMALS; ARTHRITIS, RHEUMATOID; HUMANS; INFLAMMATION; INFLAMMATORY BOWEL DISEASES; INTERLEUKIN-12; INTERLEUKIN-12 SUBUNIT P40; INTERLEUKIN-17; INTERLEUKIN-23; MICE; NEOPLASMS; PSORIASIS; TH1 CELLS; TH17 CELLS;

EID: 84908027127     PISSN: 13596101     EISSN: 18790305     Source Type: Journal    
DOI: 10.1016/j.cytogfr.2014.07.017     Document Type: Short Survey

References (112)

1. Croxford A.L., Mair F., Becher B. IL-23: one cytokine in control of autoimmunity. Eur J Immunol 2012, 42:2263-2273.
2. Krummen M., Balkow S., Shen L., Heinz S., Loquai C., Probst H.C., et al. Release of IL-12 by dendritic cells activated by TLR ligation is dependent on MyD88 signaling, whereas TRIF signaling is indispensable for TLR synergy. J Leukoc Biol 2010, 88:189-199.
3. Zhou L., Ivanov I.I., Spolski R., Min R., Shenderov K., Egawa T., et al. IL-6 programs T(H)-17 cell differentiation by promoting sequential engagement of the IL-21 and IL-23 pathways. Nat Immunol 2007, 8:967-974.
4. Gyulveszi G., Haak S., Becher B. IL-23-driven encephalo-tropism and Th17 polarization during CNS-inflammation in vivo. Eur J Immunol 2009, 39:1864-1869.
5. Colgan J., Rothman P. All in the family: IL-27 suppression of T(H)-17 cells. Nat Immunol 2006, 7:899-901.
6. Pflanz S., Timans J.C., Cheung J., Rosales R., Kanzler H., Gilbert J., et al. IL-27, a heterodimeric cytokine composed of EBI3 and p28 protein, induces proliferation of naive CD4+ T cells. Immunity 2002, 16:779-790.
7. Codarri L., Gyulveszi G., Tosevski V., Hesske L., Fontana A., Magnenat L., et al. RORgammat drives production of the cytokine GM-CSF in helper T cells, which is essential for the effector phase of autoimmune neuroinflammation. Nat Immunol 2011, 12:560-567.
8. Mascanfroni I.D., Yeste A., Vieira S.M., Burns E.J., Patel B., Sloma I., et al. IL-27 acts on DCs to suppress the T cell response and autoimmunity by inducing expression of the immunoregulatory molecule CD39. Nat Immunol 2013, 14:1054-1063.
9. Collison L.W., Workman C.J., Kuo T.T., Boyd K., Wang Y., Vignali K.M., et al. The inhibitory cytokine IL-35 contributes to regulatory T-cell function. Nature 2007, 450:566-569.
10. Shen P., Roch T., Lampropoulou V., O'Connor R.A., Stervbo U., Hilgenberg E., et al. IL-35-producing B cells are critical regulators of immunity during autoimmune and infectious diseases. Nature 2014, 507:366-370.
11. Collison L.W., Vignali D.A. Interleukin-35: odd one out or part of the family?. Immunol Rev 2008, 226:248-262.
12. Bettini M., Castellaw A.H., Lennon G.P., Burton A.R., Vignali D.A. Prevention of autoimmune diabetes by ectopic pancreatic beta-cell expression of interleukin-35. Diabetes 2012, 61:1519-1526.
13. Steinman L. Multiple sclerosis: a coordinated immunological attack against myelin in the central nervous system. Cell 1996, 85:299-302.
14. Adorini L. Interleukin-12, a key cytokine in Th1-mediated autoimmune diseases. Cell Mol Life Sci 1999, 55:1610-1625.
15. Kroenke M.A., Carlson T.J., Andjelkovic A.V., Segal B.M. IL-12- and IL-23-modulated T cells induce distinct types of EAE based on histology, CNS chemokine profile, and response to cytokine inhibition. J Exp Med 2008, 205:1535-1541.
16. Leonard J.P., Waldburger K.E., Goldman S.J. Prevention of experimental autoimmune encephalomyelitis by antibodies against interleukin 12. J Exp Med 1995, 181:381-386.
17. Segal B.M., Constantinescu C.S., Raychaudhuri A., Kim L., Fidelus-Gort R., Kasper L.H. Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study. Lancet Neurol 2008, 7:796-804.
18. Becher B., Durell B.G., Noelle R.J. Experimental autoimmune encephalitis and inflammation in the absence of interleukin-12. J Clin Invest 2002, 110:493-497.
19. Cua D.J., Sherlock J., Chen Y., Murphy C.A., Joyce B., Seymour B., et al. Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature 2003, 421:744-748.
20. McGeachy M.J., Bak-Jensen K.S., Chen Y., Tato C.M., Blumenschein W., McClanahan T., et al. TGF-beta and IL-6 drive the production of IL-17 and IL-10 by T cells and restrain T(H)-17 cell-mediated pathology. Nat Immunol 2007, 8:1390-1397.
21. McGeachy M.J., Chen Y., Tato C.M., Laurence A., Joyce-Shaikh B., Blumenschein W.M., et al. The interleukin 23 receptor is essential for the terminal differentiation of interleukin 17-producing effector T helper cells in vivo. Nat Immunol 2009, 10:314-324.
22. Becher B., Durell B.G., Noelle R.J. IL-23 produced by CNS-resident cells controls T cell encephalitogenicity during the effector phase of experimental autoimmune encephalomyelitis. J Clin Invest 2003, 112:1186-1191.
23. Martin R. Neutralisation of IL12 p40 or IL23 p40 does not block inflammation in multiple sclerosis. Lancet Neurol 2008, 7:765-766.
24. Manel N., Unutmaz D., Littman D.R. The differentiation of human T(H)-17 cells requires transforming growth factor-beta and induction of the nuclear receptor RORgammat. Nat Immunol 2008, 9:641-649.
25. Lowes M.A., Suarez-Farinas M., Krueger J.G. Immunology of psoriasis. Annu Rev Immunol 2014, 32:227-255.
26. Kagami S., Rizzo H.L., Lee J.J., Koguchi Y., Blauvelt A. Circulating Th17, Th22, and Th1 cells are increased in psoriasis. J Invest Dermatol 2010, 130:1373-1383.
27. Austin L.M., Ozawa M., Kikuchi T., Walters I.B., Krueger J.G. The majority of epidermal T cells in Psoriasis vulgaris lesions can produce type 1 cytokines, interferon-gamma, interleukin-2, and tumor necrosis factor-alpha, defining TC1 (cytotoxic T lymphocyte) and TH1 effector populations: a type 1 differentiation bias is also measured in circulating blood T cells in psoriatic patients. J Invest Dermatol 1999, 113:752-759.
28. Zaba L.C., Fuentes-Duculan J., Eungdamrong N.J., Abello M.V., Novitskaya I., Pierson K.C., et al. Psoriasis is characterized by accumulation of immunostimulatory and Th1/Th17 cell-polarizing myeloid dendritic cells. J Invest Dermatol 2009, 129:79-88.
29. Perera G.K., Di Meglio P., Nestle F.O. Psoriasis. Annu Rev Pathol 2012, 7:385-422.
30. Yawalkar N., Tscharner G.G., Hunger R.E., Hassan A.S. Increased expression of IL-12p70 and IL-23 by multiple dendritic cell and macrophage subsets in plaque psoriasis. J Dermatol Sci 2009, 54:99-105.
31. Piskin G., Sylva-Steenland R.M., Bos J.D., Teunissen M.B. In vitro and in situ expression of IL-23 by keratinocytes in healthy skin and psoriasis lesions: enhanced expression in psoriatic skin. J Immunol 2006, 176:1908-1915.
32. Papp K.A., Langley R.G., Lebwohl M., Krueger G.G., Szapary P., Yeilding N., et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 2008, 371:1675-1684.
33. Griffiths C.E., Strober B.E., van de Kerkhof P., Ho V., Fidelus-Gort R., Yeilding N., et al. Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. N Engl J Med 2010, 362:118-128.
34. Papp K.A., Griffiths C.E., Gordon K., Lebwohl M., Szapary P.O., Wasfi Y., et al. Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up. Br J Dermatol 2013, 168:844-854.
35. Kimball A.B., Gordon K.B., Langley R.G., Menter A., Chartash E.K., Valdes J. Safety and efficacy of ABT-874, a fully human interleukin 12/23 monoclonal antibody, in the treatment of moderate to severe chronic plaque psoriasis: results of a randomized, placebo-controlled, phase 2 trial. Arch Dermatol 2008, 144:200-207.
36. Gordon K.B., Langley R.G., Gottlieb A.B., Papp K.A., Krueger G.G., Strober B.E., et al. A phase III, randomized, controlled trial of the fully human IL-12/23 mAb briakinumab in moderate-to-severe psoriasis. J Invest Dermatol 2012, 132:304-314.
37. Di Cesare A., Di Meglio P., Nestle F.O. The IL-23/Th17 axis in the immunopathogenesis of psoriasis. J Invest Dermatol 2009, 129:1339-1350.
38. Chan J.R., Blumenschein W., Murphy E., Diveu C., Wiekowski M., Abbondanzo S., et al. IL-23 stimulates epidermal hyperplasia via TNF and IL-20R2-dependent mechanisms with implications for psoriasis pathogenesis. J Exp Med 2006, 203:2577-2587.
39. Pantelyushin S., Haak S., Ingold B., Kulig P., Heppner F.L., Navarini A.A., et al. Rorgammat+ innate lymphocytes and gammadelta T cells initiate psoriasiform plaque formation in mice. J Clin Invest 2012, 122:2252-2256.
40. Cai Y., Shen X., Ding C., Qi C., Li K., Li X., et al. Pivotal role of dermal IL-17-producing gammadelta T cells in skin inflammation. Immunity 2011, 35:596-610.
41. van der Fits L., Mourits S., Voerman J.S., Kant M., Boon L., Laman J.D., et al. Imiquimod-induced psoriasis-like skin inflammation in mice is mediated via the IL-23/IL-17 axis. J Immunol 2009, 182:5836-5845.
42. Lee E., Trepicchio W.L., Oestreicher J.L., Pittman D., Wang F., Chamian F., et al. Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris. J Exp Med 2004, 199:125-130.
43. Capon F., Di Meglio P., Szaub J., Prescott N.J., Dunster C., Baumber L., et al. Sequence variants in the genes for the interleukin-23 receptor (IL23R) and its ligand (IL12B) confer protection against psoriasis. Hum Genet 2007, 122:201-206.
44. Cargill M., Schrodi S.J., Chang M., Garcia V.E., Brandon R., Callis K.P., et al. A large-scale genetic association study confirms IL12B and leads to the identification of IL23R as psoriasis-risk genes. Am J Hum Genet 2007, 80:273-290.
45. Nair R.P., Duffin K.C., Helms C., Ding J., Stuart P.E., Goldgar D., et al. Genome-wide scan reveals association of psoriasis with IL-23 and NF-kappaB pathways. Nat Genet 2009, 41:199-204.
46. Gray E.E., Suzuki K., Cyster J.G. Cutting edge: identification of a motile IL-17-producing gammadelta T cell population in the dermis. J Immunol 2011, 186:6091-6095.
47. Laggner U., Di Meglio P., Perera G.K., Hundhausen C., Lacy K.E., Ali N., et al. Identification of a novel proinflammatory human skin-homing Vgamma9Vdelta2 T cell subset with a potential role in psoriasis. J Immunol 2011, 187:2783-2793.
48. Papp K.A., Leonardi C., Menter A., Ortonne J.P., Krueger J.G., Kricorian G., et al. Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis. N Engl J Med 2012, 366:1181-1189.
49. Leonardi C., Matheson R., Zachariae C., Cameron G., Li L., Edson-Heredia E., et al. Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. N Engl J Med 2012, 366:1190-1199.
50. Hueber W., Patel D.D., Dryja T., Wright A.M., Koroleva I., Bruin G., et al. Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis. Sci Transl Med 2010, 2:52ra72.
51. Sofen H., Smith S., Matheson R.T., Leonardi C.L., Calderon C., Brodmerkel C., et al. Guselkumab (an IL-23-specific mAb) demonstrates clinical and molecular response in patients with moderate-to-severe psoriasis. J Allergy Clin Immunol 2014, 133:1032-1040.
52. Parronchi P., Romagnani P., Annunziato F., Sampognaro S., Becchio A., Giannarini L., et al. Type 1 T-helper cell predominance and interleukin-12 expression in the gut of patients with Crohn's disease. Am J Pathol 1997, 150:823-832.
53. Fuss I.J., Becker C., Yang Z., Groden C., Hornung R.L., Heller F., et al. Both IL-12p70 and IL-23 are synthesized during active Crohn's disease and are down-regulated by treatment with anti-IL-12 p40 monoclonal antibody. Inflamm Bowel Dis 2006, 12:9-15.
54. Neurath M.F., Fuss I., Kelsall B.L., Stuber E., Strober W. Antibodies to interleukin 12 abrogate established experimental colitis in mice. J Exp Med 1995, 182:1281-1290.
55. Camoglio L., Juffermans N.P., Peppelenbosch M., te Velde A.A., ten Kate F.J., van Deventer S.J., et al. Contrasting roles of IL-12p40 and IL-12p35 in the development of hapten-induced colitis. Eur J Immunol 2002, 32:261-269.
56. Becker C., Dornhoff H., Neufert C., Fantini M.C., Wirtz S., Huebner S., et al. Cutting edge: IL-23 cross-regulates IL-12 production in T cell-dependent experimental colitis. J Immunol 2006, 177:2760-2764.
57. Ahern P.P., Schiering C., Buonocore S., McGeachy M.J., Cua D.J., Maloy K.J., et al. Interleukin-23 drives intestinal inflammation through direct activity on T cells. Immunity 2010, 33:279-288.
58. Geremia A., Arancibia-Carcamo C.V., Fleming M.P., Rust N., Singh B., Mortensen N.J., et al. IL-23-responsive innate lymphoid cells are increased in inflammatory bowel disease. J Exp Med 2011, 208:1127-1133.
59. Sandborn W.J., Feagan B.G., Fedorak R.N., Scherl E., Fleisher M.R., Katz S., et al. A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease. Gastroenterology 2008, 135:1130-1141.
60. Petrovic-Rackov L., Pejnovic N. Clinical significance of IL-18, IL-15, IL-12 and TNF-alpha measurement in rheumatoid arthritis. Clin Rheumatol 2006, 25:448-452.
61. Yin Z., Siegert S., Neure L., Grolms M., Liu L., Eggens U., et al. The elevated ratio of interferon gamma-/interleukin-4-positive T cells found in synovial fluid and synovial membrane of rheumatoid arthritis patients can be changed by interleukin-4 but not by interleukin-10 or transforming growth factor beta. Rheumatology (Oxf) 1999, 38:1058-1067.
62. Leipe J., Grunke M., Dechant C., Reindl C., Kerzendorf U., Schulze-Koops H., et al. Role of Th17 cells in human autoimmune arthritis. Arthritis Rheum 2010, 62:2876-2885.
63. Simons D.M., Oh S., Kropf E., Aitken M., Garcia V., Basehoar A., et al. Autoreactive Th1 cells activate monocytes to support regional Th17 responses in inflammatory arthritis. J Immunol 2013, 190:3134-3141.
64. Genovese M.C., Van den Bosch F., Roberson S.A., Bojin S., Biagini I.M., Ryan P., et al. LY2439821, a humanized anti-interleukin-17 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a phase I randomized, double-blind, placebo-controlled, proof-of-concept study. Arthritis Rheum 2010, 62:929-939.
65. Seitz M., Manz G., Franke M. [Use of recombinant human gamma interferon in patients with rheumatoid arthritis]. Z Rheumatol 1986, 45:93-99.
66. Shahrara S., Huang Q., Mandelin A.M., Pope R.M. TH-17 cells in rheumatoid arthritis. Arthritis Res Ther 2008, 10:R93.
67. Krausz S., Boumans M.J., Gerlag D.M., Lufkin J., van Kuijk A.W., Bakker A., et al. Brief report: a phase IIa, randomized, double-blind, placebo-controlled trial of apilimod mesylate, an interleukin-12/interleukin-23 inhibitor, in patients with rheumatoid arthritis. Arthritis Rheum 2012, 64:1750-1755.
68. Boyman O., Surh C.D., Sprent J. Potential use of IL-2/anti-IL-2 antibody immune complexes for the treatment of cancer and autoimmune disease. Expert Opin Biol Ther 2006, 6:1323-1331.
69. Mocellin S., Pasquali S., Rossi C.R., Nitti D. Interferon alpha adjuvant therapy in patients with high-risk melanoma: a systematic review and meta-analysis. J Natl Cancer Inst 2010, 102:493-501.
70. Fisher R.I., Rosenberg S.A., Fyfe G. Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma. Cancer J Sci Am 2000, 6(Suppl. 1):S55-S57.
71. Jinushi M., Tahara H. Cytokine gene-mediated immunotherapy: current status and future perspectives. Cancer Sci 2009, 100:1389-1396.
72. Airoldi I., Di Carlo E., Cocco C., Sorrentino C., Fais F., Cilli M., et al. Lack of Il12rb2 signaling predisposes to spontaneous autoimmunity and malignancy. Blood 2005, 106:3846-3853.
73. Cavallo F., Signorelli P., Giovarelli M., Musiani P., Modesti A., Brunda M.J., et al. Antitumor efficacy of adenocarcinoma cells engineered to produce interleukin 12 (IL-12) or other cytokines compared with exogenous IL-12. J Natl Cancer Inst 1997, 89:1049-1058.
74. Eisenring M., vom Berg J., Kristiansen G., Saller E., Becher B. IL-12 initiates tumor rejection via lymphoid tissue-inducer cells bearing the natural cytotoxicity receptor NKp46. Nat Immunol 2010, 11:1030-1038.
75. Zilocchi C., Stoppacciaro A., Chiodoni C., Parenza M., Terrazzini N., Colombo M.P. Interferon gamma-independent rejection of interleukin 12-transduced carcinoma cells requires CD4+ T cells and Granulocyte/Macrophage colony-stimulating factor. J Exp Med 1998, 188:133-143.
76. Vom Berg J., Vrohlings M., Haller S., Haimovici A., Kulig P., Sledzinska A., et al. Intratumoral IL-12 combined with CTLA-4 blockade elicits T cell-mediated glioma rejection. J Exp Med 2013, 210:2803-2811.
77. Colombo M.P., Trinchieri G. Interleukin-12 in anti-tumor immunity and immunotherapy. Cytokine Growth Factor Rev 2002, 13:155-168.
78. Smyth M.J., Taniguchi M., Street S.E. The anti-tumor activity of IL-12: mechanisms of innate immunity that are model and dose dependent. J Immunol 2000, 165:2665-2670.
79. Boggio K., Di Carlo E., Rovero S., Cavallo F., Quaglino E., Lollini P.L., et al. Ability of systemic interleukin-12 to hamper progressive stages of mammary carcinogenesis in HER2/neu transgenic mice. Cancer Res 2000, 60:359-364.
80. Grivennikov S.I., Greten F.R., Karin M. Immunity, inflammation, and cancer. Cell 2010, 140:883-899.
81. Yu H., Pardoll D., Jove R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer 2009, 9:798-809.
82. Lesina M., Kurkowski M.U., Ludes K., Rose-John S., Treiber M., Kloppel G., et al. Stat3/Socs3 activation by IL-6 transsignaling promotes progression of pancreatic intraepithelial neoplasia and development of pancreatic cancer. Cancer Cell 2011, 19:456-469.
83. Fukuda A., Wang S.C., Morris JPt, Folias A.E., Liou A., Kim G.E., et al. Stat3 and MMP7 contribute to pancreatic ductal adenocarcinoma initiation and progression. Cancer Cell 2011, 19:441-455.
84. Kortylewski M., Kujawski M., Wang T., Wei S., Zhang S., Pilon-Thomas S., et al. Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity. Nat Med 2005, 11:1314-1321.
85. Li J., Lau G., Chen L., Yuan Y.F., Huang J., Luk J.M., et al. Interleukin 23 promotes hepatocellular carcinoma metastasis via NF-kappa B induced matrix metalloproteinase 9 expression. PLoS ONE 2012, 7:e46264.
86. Ljujic B., Radosavljevic G., Jovanovic I., Pavlovic S., Zdravkovic N., Milovanovic M., et al. Elevated serum level of IL-23 correlates with expression of VEGF in human colorectal carcinoma. Arch Med Res 2010, 41:182-189.
87. Langowski J.L., Zhang X., Wu L., Mattson J.D., Chen T., Smith K., et al. IL-23 promotes tumour incidence and growth. Nature 2006, 442:461-465.
88. Gangemi S., Minciullo P., Adamo B., Franchina T., Ricciardi G.R., Ferraro M., et al. Clinical significance of circulating interleukin-23 as a prognostic factor in breast cancer patients. J Cell Biochem 2012, 113:2122-2125.
89. Xu Y., Liu Y., Pan S., Liu L., Liu J., Zhai X., et al. IL-23R polymorphisms, HBV infection, and risk of hepatocellular carcinoma in a high-risk Chinese population. J Gastroenterol 2013, 48:125-131.
90. Chu H., Cao W., Chen W., Pan S., Xiao Y., Liu Y., et al. Potentially functional polymorphisms in IL-23 receptor and risk of esophageal cancer in a Chinese population. Int J Cancer 2012, 130:1093-1097.
91. Chen J., Lu Y., Zhang H., Ding Y., Ren C., Hua Z., et al. A nonsynonymous polymorphism in IL23R gene is associated with risk of gastric cancer in a Chinese population. Mol Carcinog 2010, 49:862-868.
92. Wang L., Yi T., Kortylewski M., Pardoll D.M., Zeng D., Yu H. IL-17 can promote tumor growth through an IL-6-Stat3 signaling pathway. J Exp Med 2009, 206:1457-1464.
93. Martin-Orozco N., Muranski P., Chung Y., Yang X.O., Yamazaki T., Lu S., et al. T helper 17 cells promote cytotoxic T cell activation in tumor immunity. Immunity 2009, 31:787-798.
94. Grivennikov S.I., Wang K., Mucida D., Stewart C.A., Schnabl B., Jauch D., et al. Adenoma-linked barrier defects and microbial products drive IL-23/IL-17-mediated tumour growth. Nature 2012, 491:254-258.
95. Teng M.W., Andrews D.M., McLaughlin N., von Scheidt B., Ngiow S.F., Moller A., et al. IL-23 suppresses innate immune response independently of IL-17A during carcinogenesis and metastasis. Proc Natl Acad Sci U S A 2010, 107:8328-8333.
96. Pasche N., Frey K., Neri D. The targeted delivery of IL17 to the mouse tumor neo-vasculature enhances angiogenesis but does not reduce tumor growth rate. Angiogenesis 2012, 15:165-169.
97. Oniki S., Nagai H., Horikawa T., Furukawa J., Belladonna M.L., Yoshimoto T., et al. Interleukin-23 and interleukin-27 exert quite different antitumor and vaccine effects on poorly immunogenic melanoma. Cancer Res 2006, 66:6395-6404.
98. Hu P., Hu H.D., Chen M., Peng M.L., Tang L., Tang K.F., et al. Expression of interleukins-23 and 27 leads to successful gene therapy of hepatocellular carcinoma. Mol Immunol 2009, 46:1654-1662.
99. Cocco C., Canale S., Frasson C., Di Carlo E., Ognio E., Ribatti D., et al. Interleukin-23 acts as antitumor agent on childhood B-acute lymphoblastic leukemia cells. Blood 2010, 116:3887-3898.
100. Li J., Zhang L., Zhang J., Wei Y., Li K., Huang L., et al. Interleukin 23 regulates proliferation of lung cancer cells in a concentration-dependent way in association with the interleukin-23 receptor. Carcinogenesis 2013, 34:658-666.
101. von Scheidt B., Leung P.S., Yong M.C., Zhang Y., Towne J.E., Smyth M.J., et al. Combined anti-CD40 and anti-IL-23 monoclonal antibody therapy effectively suppresses tumor growth and metastases. Cancer Res 2014, 74:2412-2421.
102. Atkins M.B., Robertson M.J., Gordon M., Lotze M.T., DeCoste M., DuBois J.S., et al. Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies. Clin Cancer Res 1997, 3:409-417.
103. Hurteau J.A., Blessing J.A., DeCesare S.L., Creasman W.T. Evaluation of recombinant human interleukin-12 in patients with recurrent or refractory ovarian cancer: a gynecologic oncology group study. Gynecol Oncol 2001, 82:7-10.
104. van Herpen C.M., Looman M., Zonneveld M., Scharenborg N., de Wilde P.C., van de Locht L., et al. Intratumoral administration of recombinant human interleukin 12 in head and neck squamous cell carcinoma patients elicits a T-helper 1 profile in the locoregional lymph nodes. Clin Cancer Res 2004, 10:2626-2635.
105. Bajetta E., Del Vecchio M., Mortarini R., Nadeau R., Rakhit A., Rimassa L., et al. Pilot study of subcutaneous recombinant human interleukin 12 in metastatic melanoma. Clin Cancer Res 1998, 4:75-85.
106. Gajewski T.F., Fallarino F., Ashikari A., Sherman M. Immunization of HLA-A2+ melanoma patients with MAGE-3 or MelanA peptide-pulsed autologous peripheral blood mononuclear cells plus recombinant human interleukin 12. Clin Cancer Res 2001, 7:895s-901s.
107. Bekaii-Saab T.S., Roda J.M., Guenterberg K.D., Ramaswamy B., Young D.C., Ferketich A.K., et al. A phase I trial of paclitaxel and trastuzumab in combination with interleukin-12 in patients with HER2/neu-expressing malignancies. Mol Cancer Ther 2009, 8:2983-2991.
108. Alatrash G., Hutson T.E., Molto L., Richmond A., Nemec C., Mekhail T., et al. Clinical and immunologic effects of subcutaneously administered interleukin-12 and interferon alfa-2b: phase I trial of patients with metastatic renal cell carcinoma or malignant melanoma. J Clin Oncol 2004, 22:2891-2900.
109. Rook A.H., Wood G.S., Yoo E.K., Elenitsas R., Kao D.M., Sherman M.L., et al. Interleukin-12 therapy of cutaneous T-cell lymphoma induces lesion regression and cytotoxic T-cell responses. Blood 1999, 94:902-908.
110. Daud A.I., DeConti R.C., Andrews S., Urbas P., Riker A.I., Sondak V.K., et al. Phase I trial of interleukin-12 plasmid electroporation in patients with metastatic melanoma. J Clin Oncol 2008, 26:5896-5903.
111. Mahvi D.M., Henry M.B., Albertini M.R., Weber S., Meredith K., Schalch H., et al. Intratumoral injection of IL-12 plasmid DNA - results of a phase I/IB clinical trial. Cancer Gene Ther 2007, 14:717-723.
112. Fallon J., Tighe R., Kradjian G., Guzman W., Bernhardt A., Neuteboom B., et al. The immunocytokine NHS-IL12 as a potential cancer therapeutic. Oncotarget 2014, 5:1869-1884.